Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 2
2004 2
2008 1
2009 2
2010 75
2011 771
2012 1699
2013 1878
2014 2007
2015 2273
2016 2267
2017 2119
2018 2232
2019 2262
2020 2261
2021 1933
2022 1361
2023 1197
2024 1401
2025 1096
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,697 results

Results by year

Filters applied: . Clear all
Page 1
Nonoperative Management of Mismatch Repair-Deficient Tumors.
Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, Weiss J, Lumish M, Temple L, Patel M, Wilde C, Saltz LB, Argiles G, Stadler Z, Artz O, Maron S, Ku G, Gu P, Janjigian YY, Molena D, Iyer G, Coleman J, Abida W, Cohen S, Soares K, Schattner M, Strong VE, Yaeger R, Paty P, Shcherba M, Sugarman R, Romesser PB, Zervoudakis A, Desai A, Segal NH, El Dika I, Widmar M, Wei I, Pappou E, Fumo G, Aparo S, Gonen M, Gollub M, Jayaprakasam VS, Kim TH, Garcia Aguilar J, Weiser M, Diaz LA Jr. Cercek A, et al. N Engl J Med. 2025 Jun 19;392(23):2297-2308. doi: 10.1056/NEJMoa2404512. Epub 2025 Apr 27. N Engl J Med. 2025. PMID: 40293177 Clinical Trial.
Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial.
Serra-Aracil X, Pericay C, Cidoncha A, Badia-Closa J, Golda T, Kreisler E, Hernández P, Targarona E, Borda-Arrizabalaga N, Reina A, Delgado S, Espín-Bassany E, Caro-Tarrago A, Gallego-Plazas J, Pascual M, Álvarez-Laso C, Guadalajara-Labajo H, Otero A, Biondo S; TAUTEM Collaborative Group. Serra-Aracil X, et al. JAMA Surg. 2025 Jul 1;160(7):783-793. doi: 10.1001/jamasurg.2025.1398. JAMA Surg. 2025. PMID: 40434784 Clinical Trial.
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.
Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, Croner RS, Bechstein WO, Neumann UP, Waldschmidt D, Boeck S, Moosmann N, Reinacher-Schick AC, Golcher H, Adler W, Semrau S, Lubgan D, Kallies A, Hecht M, Tischoff I, Tannapfel A, Frey B, Oettle H; CONKO Study Group. Fietkau R, et al. J Clin Oncol. 2025 Oct 20;43(30):3266-3278. doi: 10.1200/JCO-24-01502. Epub 2025 Aug 13. J Clin Oncol. 2025. PMID: 40802908 Clinical Trial.
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial.
Gilbert A, Adams R, Webster J, Gilbert DC, Abbott NL, Berkman L, Bottomley D, Brown SR, Casanova N, Copeland J, Falk S, Glynne-Jones R, Goh V, Hawkins MA, Khan S, Muirhead R, Rao S, Renehan AG, Richman SD, Ruddock S, Smith A, Stewart AJ, Whibley M, Wood HM, Sebag-Montefiore D, Harrison M; PLATO trial study group. Gilbert A, et al. Lancet Oncol. 2025 Jun;26(6):707-718. doi: 10.1016/S1470-2045(25)00213-X. Epub 2025 May 4. Lancet Oncol. 2025. PMID: 40334666 Free article. Clinical Trial.
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, Bouwense SAW, Brouwer-Hol L, Bruynzeel AME, Busch OR, Coene PLO, van Eijck CHJ, de Groot JWB, Haberkorn BCM, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Loosveld OJL, Luelmo SAC, Luyer MDP, Mekenkamp LJM, Mieog JSD, Nieuwenhuijs VB, Nuyttens JJME, Patijn GA, van Santvoort HC, Stommel MWJ, Versteijne E, de Vos-Geelen J, de Wilde RF, Zonderhuis BM, van der Holt B, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Janssen QP, et al. Lancet Oncol. 2025 Oct;26(10):1346-1356. doi: 10.1016/S1470-2045(25)00363-8. Epub 2025 Sep 10. Lancet Oncol. 2025. PMID: 40945523 Clinical Trial.
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study.
Yang X, Wang X, Xiao Q, Ge X, Yu N, Li J, Feng G, Zheng Z, Jiang Y, Lu L, Xia X, Deng L, Zhang T, Wang W, Liu W, Wang J, Xiao Z, Zhou Z, Bi N, Wang H, Chen C, Wang X. Yang X, et al. Cancer Biol Ther. 2025 Dec;26(1):2504726. doi: 10.1080/15384047.2025.2504726. Epub 2025 May 14. Cancer Biol Ther. 2025. PMID: 40367097 Free PMC article.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL. Post CCB, et al. Lancet Oncol. 2025 Oct;26(10):1370-1381. doi: 10.1016/S1470-2045(25)00379-1. Epub 2025 Sep 5. Lancet Oncol. 2025. PMID: 40921169 Free PMC article. Clinical Trial.
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Audisio A, Gallio C, Velenik V, Meillat H, Ruiz-Garcia E, Riesco MC, Alecha JS, Rasschaert G, Carvalho C, Randrian V, Kirac I, Hernando J, Artaç M, O'Connor JM, Waldhorn I, Braam PM, Shamseddine A, Moretto R, De la Pinta C, De Felice F, Dulskas A, Páez López-Bravo D, Vanden Bulcke A, Bock F, Deleporte A, Van Den Eynde M, Geboes KP, Loi M, Messina M, Houlzé-Laroye C, Puccini A, Pastorino A, Papamichael D, Fiore M, Sur D, Eid M, Antoun C, Salati M, Garajovà I, Jakubauskas M, Tomášek J, Sousa Pinto CM, Schwingel J, Morano F, Adams RA, Dermine A, Chau A, Javed MA, Ghidini M, Fiorica F, Montenegro P, Petrillo A, Spolverato G, Mulet Margalef N, Diaz M, Baratelli C, Puleo F, Karampeazis A, Sert F, Gilliaux Q, De Stefano A, Liberale G, Moretti L, Martinive P, Deltuvaite Thomas V, Staggs V, Saad ED, Van Laethem JL, Sclafani F; International Real-World TNT Study Consortium. Audisio A, et al. JAMA Oncol. 2025 Sep 1;11(9):1045-1054. doi: 10.1001/jamaoncol.2025.2026. JAMA Oncol. 2025. PMID: 40638097
Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial.
Laengle J, Kuehrer I, Kulu A, Kabiljo J, Ammon D, Zirnbauer R, Stift A, Herbst F, Dauser B, Monschein M, Razek P, Haegele S, Biebl M, Geinitz H, Hulla W, Kalinina P, Müllauer L, Widder J, Bittermann C, Pils D, Tamandl D, Laengle F, Schmid R, Bergmann M. Laengle J, et al. JAMA Netw Open. 2025 Aug 1;8(8):e2527769. doi: 10.1001/jamanetworkopen.2025.27769. JAMA Netw Open. 2025. PMID: 40844778 Free PMC article. Clinical Trial.
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.
Moding EJ, Shahrokh Esfahani M, Jin C, Hui AB, Nabet BY, Liu Y, Chabon JJ, Binkley MS, Kurtz DM, Hamilton EG, Chaudhuri AA, Liu CL, Li Z, Bonilla RF, Jiang AL, Lau BC, Lopez P, He J, Qiao Y, Xu T, Yao L, Gandhi S, Liao Z, Das M, Ramchandran KJ, Padda SK, Neal JW, Wakelee HA, Gensheimer MF, Loo BW Jr, Li R, Lin SH, Alizadeh AA, Diehn M. Moding EJ, et al. Cancer Discov. 2025 Aug 4;15(8):1609-1629. doi: 10.1158/2159-8290.CD-24-1704. Cancer Discov. 2025. PMID: 40299851
22,697 results
You have reached the last available page of results. Please see the User Guide for more information.